Business · 30/12/2005Updated: 10/17/2026 · 1 min read
FDA Submits Draft Guidance for Clinical Trial Data Monitoring Committees for OMB Review
Summary
The Food and Drug Administration (FDA) has submitted a proposed collection of information for review and clearance under the Paperwork Reduction Act of 1995, as part of its draft guidance for clinical trial sponsors on establishing and operating data monitoring committees.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →